Pinnacle Wealth Management Advisory Group LLC Sells 133 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Pinnacle Wealth Management Advisory Group LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 695 shares of the medical research company’s stock after selling 133 shares during the period. Pinnacle Wealth Management Advisory Group LLC’s holdings in Thermo Fisher Scientific were worth $346,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of TMO. Cypress Advisory Group LLC bought a new position in Thermo Fisher Scientific during the 4th quarter worth $253,000. GAMMA Investing LLC raised its position in Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock worth $2,419,000 after purchasing an additional 877 shares during the last quarter. Deutsche Bank AG raised its position in Thermo Fisher Scientific by 9.5% during the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company’s stock worth $687,553,000 after purchasing an additional 114,277 shares during the last quarter. Hancock Whitney Corp raised its position in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company’s stock worth $2,802,000 after acquiring an additional 30 shares in the last quarter. Finally, Cetera Trust Company N.A raised its position in shares of Thermo Fisher Scientific by 3.3% in the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company’s stock worth $2,312,000 after acquiring an additional 150 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.33% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. UBS Group lifted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, May 21st. Raymond James Financial reissued an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Evercore ISI reduced their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Six research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $593.00.

Thermo Fisher Scientific Price Performance

TMO stock opened at $484.90 on Tuesday. The company has a market capitalization of $183.04 billion, a P/E ratio of 28.05, a price-to-earnings-growth ratio of 2.56 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The business has a 50-day simple moving average of $415.18 and a two-hundred day simple moving average of $468.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 EPS. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.